IL7R and acute lymphoblastic leukemia: Therefore, numerous T-ALL patients could still benefit from these novel compounds targeting RAS pathway activation downstream of deregulated signaling from cytokine or growth factor receptors (i.e., IL-7R, IGFR1) frequently found in T-ALL (Figure 3).